Cargando…

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

AIMS: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile...

Descripción completa

Detalles Bibliográficos
Autores principales: Senni, Michele, Lopez‐Sendon, Jose, Cohen‐Solal, Alain, Ponikowski, Piotr, Nkulikiyinka, Richard, Freitas, Cecilia, Vlajnic, Vanja Miodrag, Roessig, Lothar, Pieske, Burkert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773767/
https://www.ncbi.nlm.nih.gov/pubmed/35880474
http://dx.doi.org/10.1002/ehf2.14050
_version_ 1784855261032218624
author Senni, Michele
Lopez‐Sendon, Jose
Cohen‐Solal, Alain
Ponikowski, Piotr
Nkulikiyinka, Richard
Freitas, Cecilia
Vlajnic, Vanja Miodrag
Roessig, Lothar
Pieske, Burkert
author_facet Senni, Michele
Lopez‐Sendon, Jose
Cohen‐Solal, Alain
Ponikowski, Piotr
Nkulikiyinka, Richard
Freitas, Cecilia
Vlajnic, Vanja Miodrag
Roessig, Lothar
Pieske, Burkert
author_sort Senni, Michele
collection PubMed
description AIMS: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile [Q4]. METHODS AND RESULTS: VICTORIA participants with available baseline NT‐proBNP levels (n = 4805; 95.1% of total) were included. Compared with patients in Q1–Q3 (NT‐proBNP: Q1, ≤1556 pg/mL; Q2, >1556–2816 pg/mL; and Q3, >2816–5314 pg/mL), patients in Q4 (NT‐proBNP: >5314 pg/mL) were older (69.2 ± 12.0 vs. 66.6 ± 12.1 years), had lower mean ejection fraction (27.2 ± 8.3% vs. 29.5 ± 8.2%; P < 0.0001), and were more likely to be in New York Heart Association (NYHA) Class III (51.8 vs. 35.6%) or IV (2.4 vs. 1.0%). Compared with Q1–Q3, patients in Q4 had higher mean Meta‐Analysis Global Group in Chronic Heart Failure risk score (27.3 ± 6.6 vs. 23.5 ± 6.4; P < 0.0001), had lower mean estimated glomerular filtration rate (eGFR; 51.5 ± 25.5 vs. 65.0 ± 26.8 mL/min/1.73 m(2); P < 0.0001) and haemoglobin (12.8 ± 2.0 vs. 13.6 ± 1.9 g/dL; P < 0.0001), and more had atrial fibrillation (48.7% vs. 43.1%; P = 0.0007) and were randomized while hospitalized for HF (14.8 vs. 9.9%; P < 0.0001). Target dose was achieved in 72.3 and 63.7% of patients in Q1–Q3 and Q4, respectively (P < 0.0001). Primary outcome (composite of time to cardiovascular death or first HF hospitalization) rates were 24.5 and 31.7 per 100 patient‐years for vericiguat and placebo in Q1–Q3 [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.69–0.88, P < 0.001] and 73.6 and 63.6 in Q4 (HR 1.15; 95% CI 0.99–1.34, P = 0.070). Serious adverse events were more frequent in NT‐proBNP Q4 (total population) compared with Q1–Q3 (38.3 vs. 32.3%; P = 0.0001), driven mainly by the placebo group. Adverse events leading to death were more frequent in Q4 than Q1–Q3 (5.8 vs. 2.4%; P < 0.0001). CONCLUSIONS: Plasma NT‐proBNP may help identify patients with worsening HF with reduced ejection fraction, in whom the beneficial effects of vericiguat may be highest. Patients with highest NT‐proBNP values are probably too far advanced, suffering more co‐morbidities, or still clinically unstable after decompensation to derive benefit from vericiguat.
format Online
Article
Text
id pubmed-9773767
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97737672022-12-23 Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial Senni, Michele Lopez‐Sendon, Jose Cohen‐Solal, Alain Ponikowski, Piotr Nkulikiyinka, Richard Freitas, Cecilia Vlajnic, Vanja Miodrag Roessig, Lothar Pieske, Burkert ESC Heart Fail Original Articles AIMS: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile [Q4]. METHODS AND RESULTS: VICTORIA participants with available baseline NT‐proBNP levels (n = 4805; 95.1% of total) were included. Compared with patients in Q1–Q3 (NT‐proBNP: Q1, ≤1556 pg/mL; Q2, >1556–2816 pg/mL; and Q3, >2816–5314 pg/mL), patients in Q4 (NT‐proBNP: >5314 pg/mL) were older (69.2 ± 12.0 vs. 66.6 ± 12.1 years), had lower mean ejection fraction (27.2 ± 8.3% vs. 29.5 ± 8.2%; P < 0.0001), and were more likely to be in New York Heart Association (NYHA) Class III (51.8 vs. 35.6%) or IV (2.4 vs. 1.0%). Compared with Q1–Q3, patients in Q4 had higher mean Meta‐Analysis Global Group in Chronic Heart Failure risk score (27.3 ± 6.6 vs. 23.5 ± 6.4; P < 0.0001), had lower mean estimated glomerular filtration rate (eGFR; 51.5 ± 25.5 vs. 65.0 ± 26.8 mL/min/1.73 m(2); P < 0.0001) and haemoglobin (12.8 ± 2.0 vs. 13.6 ± 1.9 g/dL; P < 0.0001), and more had atrial fibrillation (48.7% vs. 43.1%; P = 0.0007) and were randomized while hospitalized for HF (14.8 vs. 9.9%; P < 0.0001). Target dose was achieved in 72.3 and 63.7% of patients in Q1–Q3 and Q4, respectively (P < 0.0001). Primary outcome (composite of time to cardiovascular death or first HF hospitalization) rates were 24.5 and 31.7 per 100 patient‐years for vericiguat and placebo in Q1–Q3 [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.69–0.88, P < 0.001] and 73.6 and 63.6 in Q4 (HR 1.15; 95% CI 0.99–1.34, P = 0.070). Serious adverse events were more frequent in NT‐proBNP Q4 (total population) compared with Q1–Q3 (38.3 vs. 32.3%; P = 0.0001), driven mainly by the placebo group. Adverse events leading to death were more frequent in Q4 than Q1–Q3 (5.8 vs. 2.4%; P < 0.0001). CONCLUSIONS: Plasma NT‐proBNP may help identify patients with worsening HF with reduced ejection fraction, in whom the beneficial effects of vericiguat may be highest. Patients with highest NT‐proBNP values are probably too far advanced, suffering more co‐morbidities, or still clinically unstable after decompensation to derive benefit from vericiguat. John Wiley and Sons Inc. 2022-07-26 /pmc/articles/PMC9773767/ /pubmed/35880474 http://dx.doi.org/10.1002/ehf2.14050 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Senni, Michele
Lopez‐Sendon, Jose
Cohen‐Solal, Alain
Ponikowski, Piotr
Nkulikiyinka, Richard
Freitas, Cecilia
Vlajnic, Vanja Miodrag
Roessig, Lothar
Pieske, Burkert
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title_full Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title_fullStr Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title_full_unstemmed Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title_short Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
title_sort vericiguat and nt‐probnp in patients with heart failure with reduced ejection fraction: analyses from the victoria trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773767/
https://www.ncbi.nlm.nih.gov/pubmed/35880474
http://dx.doi.org/10.1002/ehf2.14050
work_keys_str_mv AT sennimichele vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT lopezsendonjose vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT cohensolalalain vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT ponikowskipiotr vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT nkulikiyinkarichard vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT freitascecilia vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT vlajnicvanjamiodrag vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT roessiglothar vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial
AT pieskeburkert vericiguatandntprobnpinpatientswithheartfailurewithreducedejectionfractionanalysesfromthevictoriatrial